Advertisement
Advertisement
U.S. markets open in 8 hours 42 minutes
Advertisement
Advertisement
Advertisement
Advertisement

Bionano Genomics, Inc. (BNGO)

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
Add to watchlist
4.0000-0.0900 (-2.20%)
At close: 1:00PM EST
4.0100 +0.01 (+0.25%)
After hours: 04:56PM EST
Advertisement
Sign in to post a message.
  • P
    Paul
    Exert From Article

    EB: How do you think the market/industry sector will change? Are there any speculations in terms of major collaborations or acquisitions we will see in the near or far future that may potentially compete with your new combined offering?
    SS: We at BioDiscovery have had a great and close collaboration going on with Illumina  over the past year. We designed a new cytogenetic microarray with Illumina, which is just about to be marketed more actively. This is the first new cytogenetic microarray on the market in at least ten years. It has a lot of significant advantages over the legacy products. Bionano, is completely open and interested to continue expanding this market because the BioDiscovery/Illumina relationship is complementary to what they are doing and it expands both microarray and NGS applications. This, of course, will also result in a strong glue between Bionano and Illumina. This strong, collaborative partnership will be of benefit to the entire community.

    https://enlightenbio.blog/2021/11/23/bionano-genomics-acquiring-biodiscovery-the-perfect-alignment-of-the-stars/
  • g
    gregory
    How manipulated is this stock? NNDM is up 10% on 109% increase in revenue. They build 3d printers. BNGO 112% revenue increase and here we are. Game changing diagnostic abilities to cure illness and disease vs 3d printers.
  • D
    Daniel
    The whole market will spike on Monday

    Panic sellers were overreacting today
  • P
    Peter
    There is a cost dynamic to consider. Say a lab provider gets payer reimbursement of $10,000 for a cytogenomics test using the current technology (FISH, CMA, Karyotyping) and they net $1,000. But if the provider uses Saphyr they net $5,000. That's great for a while until the payer catches on that there's a cheaper way to get the same or better results. The payer would then lower its reimbursement schedule for that provider - and all other lab providers because the payer knows the test result can be obtained at a much lower price. Therefore, Saphyr at first would be a road to greater profits but eventually would not be optional for any provider - it would be NECESSARY!!

    If anyone can show some example LDT pricing for cytogenomics testing that would be interesting to know. Even better to know, the net cost of current technology versus Saphyr.
  • R
    ROBERTO
    Before Ronnie start making bad comments please note the market is red for everyone and this is not related to anything wrong with BNGO
    Bullish
  • M
    Mentz
    This board is too funny. I love the doom and gloom. Has anyone looked at other small caps? Drops are significant across the board. Here are you options: buy more, sell, or hold. My losses are at 70%
  • R
    Ross L
    The findings by OGM were concordant with those obtained by CMA and NGS for copy number variants (CNVs) and FISH and karyotyping for balanced structural variations (SVs) such as inversions and translocations. Sensitivity compared to CMA was 96% (22/23 CNVs detected) excluding copy neutral loss of heterozygosity calls. Sensitivity compared to karyotyping and FISH was 100% (98/98 loci detected). OGM also revealed substantially more SVs than the traditional methods, including an additional 51 CNVs and 20 SVs.

    https://finance.yahoo.com/news/bionano-genomics-announces-peer-reviewed-130000446.html
    SAN DIEGO, Nov. 22, 2021 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (BNGO), provider of optical genome mapping (OGM) solutions on the Saphyr® system and the leading software for genomic data visualization, interpretation and reporting, today announce
    SAN DIEGO, Nov. 22, 2021 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (BNGO), provider of optical genome mapping (OGM) solutions on the Saphyr® system and the leading software for genomic data visualization, interpretation and reporting, today announce
    finance.yahoo.com
  • V
    VICTOR
    Bionano’s Is on Track for Growth Thanks to Saphyr As I see it, the market at large is missing the forest for the trees. For the quarter ending Sep. 30, Bionano generated $4.7 million in sales, up 112% year-over-year. Just like what played out last quarter, this early stage company has once again posted triple-digit-percentage revenue growth. This was the sixth quarter in a row that the company has beat analyst revenue estimates. These strong results are due to increased installations of its Saphyr optical genome mapping (OGM) instrument. At this price it is a great buy... GO BNGO
  • d
    dennis
    Bngo stock price got ahead of itself over a year ago but I love the strategy and execution over the last few quarters. They have a partnership with illumina through BioDiscovery and prior big sales to illumina. They will launch first version of software in q1 that combines ngs and ogm reads. They will release more robust version in 2022. They will test new hardware in q4, release beta in q1 and then add robotics resulting in 10x throughput. They are testing probes to see if they can see snv. Creating ldt’s. 130 articles and presentations in 3 quarters.
    Bullish
  • M
    Michael
    I love these that think they can pick the low on the stock. Yeah maybe it goes lower and maybe not. But if you sold one thing is for sure and that is you won’t buy back at the low and it’s much more likely you will buy back higher if you want the stock. The tutes will buy back at the low and when a squeeze starts the price will blow past where you sold it pretty quickly
  • d
    dennis
    BNGO at 30x depth of coverage saphyr will give you 5,000 samples per year. The next-generation system instrument will go up to about 14,000 samples per year. Approx 3x.

    And then there will be a capability of clustering up to 4 of those instruments together in a robotic system that will operate continuously. And so 4x 14,000 is going to get those numbers up even more.
  • M
    Michael
    Hopkins study says OGM with Saphyr is 10,000 times more accurate than karyotyping. And 10 to 20 times more accurate than micro array. This is why the tutes want your stock!
  • T
    Todd
    I have no idea what BNGO will do Monday - I am still waiting for a tradeable bottom. That said, I think the market will be up big on Monday - even though the omicron variant is more contagious - it appears the symptoms are very mild - great news - there should be limited need to shut down over something with mild symptoms...If you get it, just like a couple of days and it passes...If anyone has heard anything different - please comment...
  • S
    S.
    there are 206 institutions holding shares I don t think they want to loose there money plus big names companies own millions of shares I guess they feel the stock has potential otherwise why invest down the road will speak for itself
    Bullish
  • 1
    11B10VN
    Looking at institutional owners shows: 1) Blackrock @ approximately 18 Million shares, 2) Vanguard @ approximately 28 Million shares throughout all their holdings. Do you think they are confident of the technology?
  • L
    Long
    When insiders keep on buying shares that means they know something big about to happen.
    Bullish
  • J
    Jay
    Holding at $12. Still not worried.
  • L
    Long
    I am not worried about the short term stock price and the overall manipulation that is happening in the market these days. BNGO is oversold and this is the time to load up the boat. I have been loading my truck! Good luck everyone
    Bullish
  • G
    Guy Coma
    Load load load the boat .

    Classic play by the tutes heaving shorting to shake weak hands and drive a sell off then load the boat at the bottom.

    Yikes if you sold just now I don’t think investing is for you 😉
    Bullish
Advertisement
Advertisement